RapamycinFungusV1, Main, Exploration, bibRecord, 001889

In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus.

Identifieur interne : 001889 ( Main/Exploration ); précédent : 001888; suivant : 001890

In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus.

Auteurs : William J. Steinbach [États-Unis] ; Wiley A. Schell ; Jill R. Blankenship ; Chiatogu Onyewu ; Joseph Heitman ; John R. Perfect

Source :

Antimicrobial agents and chemotherapy [ 0066-4804 ] ; 2004.

RBID : pubmed:15105118

Descripteurs français

KwdFr :
- Antifongiques (pharmacologie), Aspergillus fumigatus (croissance et développement), Aspergillus fumigatus (effets des médicaments et des substances chimiques), Aspergillus fumigatus (ultrastructure), Calcineurine (physiologie), Caspofungine (MeSH), Ciclosporine (pharmacologie), Inhibiteurs de la calcineurine (MeSH), Interactions médicamenteuses (MeSH), Lipopeptides (MeSH), Peptides (pharmacologie), Peptides cycliques (MeSH), Pyrimidines (pharmacologie), Synergie des médicaments (MeSH), Tacrolimus (pharmacologie), Tests de sensibilité microbienne (MeSH), Triazoles (pharmacologie), Voriconazole (MeSH), Échinocandines (MeSH).
MESH :
- croissance et développement : Aspergillus fumigatus.
- effets des médicaments et des substances chimiques : Aspergillus fumigatus.
- pharmacologie : Antifongiques, Ciclosporine, Peptides, Pyrimidines, Tacrolimus, Triazoles.
- physiologie : Calcineurine.
- ultrastructure : Aspergillus fumigatus, Caspofungine, Inhibiteurs de la calcineurine, Interactions médicamenteuses, Lipopeptides, Peptides cycliques, Synergie des médicaments, Tests de sensibilité microbienne, Voriconazole, Échinocandines.

English descriptors

KwdEn :
- Antifungal Agents (pharmacology), Aspergillus fumigatus (drug effects), Aspergillus fumigatus (growth & development), Aspergillus fumigatus (ultrastructure), Calcineurin (physiology), Calcineurin Inhibitors (MeSH), Caspofungin (MeSH), Cyclosporine (pharmacology), Drug Interactions (MeSH), Drug Synergism (MeSH), Echinocandins (MeSH), Lipopeptides (MeSH), Microbial Sensitivity Tests (MeSH), Peptides (pharmacology), Peptides, Cyclic (MeSH), Pyrimidines (pharmacology), Tacrolimus (pharmacology), Triazoles (pharmacology), Voriconazole (MeSH).
MESH :
- chemical , pharmacology : Antifungal Agents, Cyclosporine, Peptides, Pyrimidines, Tacrolimus, Triazoles.
- drug effects : Aspergillus fumigatus.
- growth & development : Aspergillus fumigatus.
- chemical , physiology : Calcineurin.
- ultrastructure : Aspergillus fumigatus.
- chemical : Calcineurin Inhibitors, Caspofungin, Drug Interactions, Drug Synergism, Echinocandins, Lipopeptides, Microbial Sensitivity Tests, Peptides, Cyclic, Voriconazole.

Abstract

The optimal treatment for invasive aspergillosis remains elusive, despite the increased efficacy of newer agents. The immunosuppressants cyclosporine (CY), tacrolimus (FK506), and sirolimus (formerly called rapamycin) exhibit in vitro and in vivo activity against Candida albicans, Cryptococcus neoformans, and Saccharomyces cerevisiae, including fungicidal synergy with azole antifungals. We report here that both FK506 and CY exhibit a clear in vitro positive interaction with caspofungin against Aspergillus fumigatus by disk diffusion, microdilution checkerboard, and gross and microscopic morphological analyses. Microscopic morphological analyses indicate that the calcineurin inhibitors delay filamentation, and in combination with caspofungin there is a positive interaction. Our findings suggest a potential role for combination therapy with calcineurin pathway inhibitors and existing antifungal agents to augment activity against A. fumigatus.

DOI: 10.1128/aac.48.5.1664-1669.2004
PubMed: 15105118
PubMed Central: PMC400573

Affiliations:

États-Unis

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 001889
to stream Main, to step Curation: 001889

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus.</title>
<author><name sortKey="Steinbach, William J" sort="Steinbach, William J" uniqKey="Steinbach W" first="William J" last="Steinbach">William J. Steinbach</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Pediatric Infectious Diseases, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA. stein022@mc.duke.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Pediatric Infectious Diseases, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710</wicri:regionArea>
<wicri:noRegion>North Carolina 27710</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Schell, Wiley A" sort="Schell, Wiley A" uniqKey="Schell W" first="Wiley A" last="Schell">Wiley A. Schell</name>
</author>
<author><name sortKey="Blankenship, Jill R" sort="Blankenship, Jill R" uniqKey="Blankenship J" first="Jill R" last="Blankenship">Jill R. Blankenship</name>
</author>
<author><name sortKey="Onyewu, Chiatogu" sort="Onyewu, Chiatogu" uniqKey="Onyewu C" first="Chiatogu" last="Onyewu">Chiatogu Onyewu</name>
</author>
<author><name sortKey="Heitman, Joseph" sort="Heitman, Joseph" uniqKey="Heitman J" first="Joseph" last="Heitman">Joseph Heitman</name>
</author>
<author><name sortKey="Perfect, John R" sort="Perfect, John R" uniqKey="Perfect J" first="John R" last="Perfect">John R. Perfect</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2004">2004</date>
<idno type="RBID">pubmed:15105118</idno>
<idno type="pmid">15105118</idno>
<idno type="pmc">PMC400573</idno>
<idno type="doi">10.1128/aac.48.5.1664-1669.2004</idno>
<idno type="wicri:Area/Main/Corpus">001889</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001889</idno>
<idno type="wicri:Area/Main/Curation">001889</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001889</idno>
<idno type="wicri:Area/Main/Exploration">001889</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus.</title>
<author><name sortKey="Steinbach, William J" sort="Steinbach, William J" uniqKey="Steinbach W" first="William J" last="Steinbach">William J. Steinbach</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Pediatric Infectious Diseases, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA. stein022@mc.duke.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Pediatric Infectious Diseases, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710</wicri:regionArea>
<wicri:noRegion>North Carolina 27710</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Schell, Wiley A" sort="Schell, Wiley A" uniqKey="Schell W" first="Wiley A" last="Schell">Wiley A. Schell</name>
</author>
<author><name sortKey="Blankenship, Jill R" sort="Blankenship, Jill R" uniqKey="Blankenship J" first="Jill R" last="Blankenship">Jill R. Blankenship</name>
</author>
<author><name sortKey="Onyewu, Chiatogu" sort="Onyewu, Chiatogu" uniqKey="Onyewu C" first="Chiatogu" last="Onyewu">Chiatogu Onyewu</name>
</author>
<author><name sortKey="Heitman, Joseph" sort="Heitman, Joseph" uniqKey="Heitman J" first="Joseph" last="Heitman">Joseph Heitman</name>
</author>
<author><name sortKey="Perfect, John R" sort="Perfect, John R" uniqKey="Perfect J" first="John R" last="Perfect">John R. Perfect</name>
</author>
</analytic>
<series><title level="j">Antimicrobial agents and chemotherapy</title>
<idno type="ISSN">0066-4804</idno>
<imprint><date when="2004" type="published">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antifungal Agents (pharmacology)</term>
<term>Aspergillus fumigatus (drug effects)</term>
<term>Aspergillus fumigatus (growth & development)</term>
<term>Aspergillus fumigatus (ultrastructure)</term>
<term>Calcineurin (physiology)</term>
<term>Calcineurin Inhibitors (MeSH)</term>
<term>Caspofungin (MeSH)</term>
<term>Cyclosporine (pharmacology)</term>
<term>Drug Interactions (MeSH)</term>
<term>Drug Synergism (MeSH)</term>
<term>Echinocandins (MeSH)</term>
<term>Lipopeptides (MeSH)</term>
<term>Microbial Sensitivity Tests (MeSH)</term>
<term>Peptides (pharmacology)</term>
<term>Peptides, Cyclic (MeSH)</term>
<term>Pyrimidines (pharmacology)</term>
<term>Tacrolimus (pharmacology)</term>
<term>Triazoles (pharmacology)</term>
<term>Voriconazole (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Antifongiques (pharmacologie)</term>
<term>Aspergillus fumigatus (croissance et développement)</term>
<term>Aspergillus fumigatus (effets des médicaments et des substances chimiques)</term>
<term>Aspergillus fumigatus (ultrastructure)</term>
<term>Calcineurine (physiologie)</term>
<term>Caspofungine (MeSH)</term>
<term>Ciclosporine (pharmacologie)</term>
<term>Inhibiteurs de la calcineurine (MeSH)</term>
<term>Interactions médicamenteuses (MeSH)</term>
<term>Lipopeptides (MeSH)</term>
<term>Peptides (pharmacologie)</term>
<term>Peptides cycliques (MeSH)</term>
<term>Pyrimidines (pharmacologie)</term>
<term>Synergie des médicaments (MeSH)</term>
<term>Tacrolimus (pharmacologie)</term>
<term>Tests de sensibilité microbienne (MeSH)</term>
<term>Triazoles (pharmacologie)</term>
<term>Voriconazole (MeSH)</term>
<term>Échinocandines (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antifungal Agents</term>
<term>Cyclosporine</term>
<term>Peptides</term>
<term>Pyrimidines</term>
<term>Tacrolimus</term>
<term>Triazoles</term>
</keywords>
<keywords scheme="MESH" qualifier="croissance et développement" xml:lang="fr"><term>Aspergillus fumigatus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Aspergillus fumigatus</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Aspergillus fumigatus</term>
</keywords>
<keywords scheme="MESH" qualifier="growth & development" xml:lang="en"><term>Aspergillus fumigatus</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antifongiques</term>
<term>Ciclosporine</term>
<term>Peptides</term>
<term>Pyrimidines</term>
<term>Tacrolimus</term>
<term>Triazoles</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Calcineurine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Calcineurin</term>
</keywords>
<keywords scheme="MESH" qualifier="ultrastructure" xml:lang="en"><term>Aspergillus fumigatus</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Calcineurin Inhibitors</term>
<term>Caspofungin</term>
<term>Drug Interactions</term>
<term>Drug Synergism</term>
<term>Echinocandins</term>
<term>Lipopeptides</term>
<term>Microbial Sensitivity Tests</term>
<term>Peptides, Cyclic</term>
<term>Voriconazole</term>
</keywords>
<keywords scheme="MESH" qualifier="ultrastructure" xml:lang="fr"><term>Aspergillus fumigatus</term>
<term>Caspofungine</term>
<term>Inhibiteurs de la calcineurine</term>
<term>Interactions médicamenteuses</term>
<term>Lipopeptides</term>
<term>Peptides cycliques</term>
<term>Synergie des médicaments</term>
<term>Tests de sensibilité microbienne</term>
<term>Voriconazole</term>
<term>Échinocandines</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The optimal treatment for invasive aspergillosis remains elusive, despite the increased efficacy of newer agents. The immunosuppressants cyclosporine (CY), tacrolimus (FK506), and sirolimus (formerly called rapamycin) exhibit in vitro and in vivo activity against Candida albicans, Cryptococcus neoformans, and Saccharomyces cerevisiae, including fungicidal synergy with azole antifungals. We report here that both FK506 and CY exhibit a clear in vitro positive interaction with caspofungin against Aspergillus fumigatus by disk diffusion, microdilution checkerboard, and gross and microscopic morphological analyses. Microscopic morphological analyses indicate that the calcineurin inhibitors delay filamentation, and in combination with caspofungin there is a positive interaction. Our findings suggest a potential role for combination therapy with calcineurin pathway inhibitors and existing antifungal agents to augment activity against A. fumigatus.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15105118</PMID>
<DateCompleted><Year>2004</Year>
<Month>06</Month>
<Day>08</Day>
</DateCompleted>
<DateRevised><Year>2019</Year>
<Month>05</Month>
<Day>09</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0066-4804</ISSN>
<JournalIssue CitedMedium="Print"><Volume>48</Volume>
<Issue>5</Issue>
<PubDate><Year>2004</Year>
<Month>May</Month>
</PubDate>
</JournalIssue>
<Title>Antimicrobial agents and chemotherapy</Title>
<ISOAbbreviation>Antimicrob Agents Chemother</ISOAbbreviation>
</Journal>
<ArticleTitle>In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus.</ArticleTitle>
<Pagination><MedlinePgn>1664-9</MedlinePgn>
</Pagination>
<Abstract><AbstractText>The optimal treatment for invasive aspergillosis remains elusive, despite the increased efficacy of newer agents. The immunosuppressants cyclosporine (CY), tacrolimus (FK506), and sirolimus (formerly called rapamycin) exhibit in vitro and in vivo activity against Candida albicans, Cryptococcus neoformans, and Saccharomyces cerevisiae, including fungicidal synergy with azole antifungals. We report here that both FK506 and CY exhibit a clear in vitro positive interaction with caspofungin against Aspergillus fumigatus by disk diffusion, microdilution checkerboard, and gross and microscopic morphological analyses. Microscopic morphological analyses indicate that the calcineurin inhibitors delay filamentation, and in combination with caspofungin there is a positive interaction. Our findings suggest a potential role for combination therapy with calcineurin pathway inhibitors and existing antifungal agents to augment activity against A. fumigatus.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Steinbach</LastName>
<ForeName>William J</ForeName>
<Initials>WJ</Initials>
<AffiliationInfo><Affiliation>Division of Pediatric Infectious Diseases, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA. stein022@mc.duke.edu</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Schell</LastName>
<ForeName>Wiley A</ForeName>
<Initials>WA</Initials>
</Author>
<Author ValidYN="Y"><LastName>Blankenship</LastName>
<ForeName>Jill R</ForeName>
<Initials>JR</Initials>
</Author>
<Author ValidYN="Y"><LastName>Onyewu</LastName>
<ForeName>Chiatogu</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Heitman</LastName>
<ForeName>Joseph</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Perfect</LastName>
<ForeName>John R</ForeName>
<Initials>JR</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>K12 HD000850</GrantID>
<Acronym>HD</Acronym>
<Agency>NICHD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>K12-HD00850</GrantID>
<Acronym>HD</Acronym>
<Agency>NICHD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>P01-AI-449175</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>AI50438</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 AI050438</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Antimicrob Agents Chemother</MedlineTA>
<NlmUniqueID>0315061</NlmUniqueID>
<ISSNLinking>0066-4804</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000935">Antifungal Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D065095">Calcineurin Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054714">Echinocandins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D055666">Lipopeptides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010455">Peptides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010456">Peptides, Cyclic</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014230">Triazoles</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>83HN0GTJ6D</RegistryNumber>
<NameOfSubstance UI="D016572">Cyclosporine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.1.3.16</RegistryNumber>
<NameOfSubstance UI="D019703">Calcineurin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>F0XDI6ZL63</RegistryNumber>
<NameOfSubstance UI="D000077336">Caspofungin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>JFU09I87TR</RegistryNumber>
<NameOfSubstance UI="D065819">Voriconazole</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>WM0HAQ4WNM</RegistryNumber>
<NameOfSubstance UI="D016559">Tacrolimus</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000935" MajorTopicYN="N">Antifungal Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001232" MajorTopicYN="N">Aspergillus fumigatus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000254" MajorTopicYN="N">growth & development</QualifierName>
<QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019703" MajorTopicYN="N">Calcineurin</DescriptorName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D065095" MajorTopicYN="N">Calcineurin Inhibitors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000077336" MajorTopicYN="N">Caspofungin</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016572" MajorTopicYN="N">Cyclosporine</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D054714" MajorTopicYN="N">Echinocandins</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055666" MajorTopicYN="N">Lipopeptides</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010456" MajorTopicYN="Y">Peptides, Cyclic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016559" MajorTopicYN="N">Tacrolimus</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014230" MajorTopicYN="N">Triazoles</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D065819" MajorTopicYN="N">Voriconazole</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year>
<Month>4</Month>
<Day>24</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2004</Year>
<Month>6</Month>
<Day>21</Day>
<Hour>10</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2004</Year>
<Month>4</Month>
<Day>24</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">15105118</ArticleId>
<ArticleId IdType="pmc">PMC400573</ArticleId>
<ArticleId IdType="doi">10.1128/aac.48.5.1664-1669.2004</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 2000 Jan;44(1):143-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10602736</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Microbiol Rev. 1999 Oct;12(4):583-611</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10515904</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2000 Mar;44(3):739-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10681348</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Med Chem Lett. 2000 Jul 3;10(13):1405-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10888319</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2000 Sep;44(9):2373-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10952582</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2000 Nov;44(11):2932-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11036003</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2001 Jan;45(1):327-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11120990</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>EMBO J. 2001 Mar 1;20(5):1020-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11230126</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2001 Mar 30;276(13):9583-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11266435</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2001 Nov;45(11):3162-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11600372</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>EMBO J. 2002 Feb 15;21(4):546-59</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11847103</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>EMBO J. 2002 May 15;21(10):2343-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12006487</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2002 Aug 8;347(6):408-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12167683</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioessays. 2002 Oct;24(10):894-903</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12325122</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Microbiol. 2002 Oct;46(1):257-68</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12366848</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2003 Jan 1;36(1):46-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12491201</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Antimicrob Chemother. 2003 Feb;51(2):313-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12562696</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Investig Drugs. 2003 Feb;4(2):192-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12669381</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2003 Oct 1;37 Suppl 3:S157-87</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12975751</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2003 Oct 1;37 Suppl 3:S188-224</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12975752</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Antibiot (Tokyo). 1975 Oct;28(10):721-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1102508</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Antibiot (Tokyo). 1975 Oct;28(10):727-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1102509</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Immun. 1985 Oct;50(1):22-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3899932</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Immun. 1988 Jan;56(1):7-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3275587</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am Rev Respir Dis. 1989 Jan;139(1):8-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2643377</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 1991 Aug 23;66(4):807-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1715244</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Transplant Proc. 1991 Dec;23(6):3040-1</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1721353</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Exp Med. 1992 Sep 1;176(3):751-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1380976</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 1993 Apr 15;268(11):7607-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7681823</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 1993 May 25;268(15):11335-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7684380</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Transplantation. 1994 Jun 27;57(12):1689-700</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7517076</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 1994 Jul;38(7):1480-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7979276</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 1997 Jan;41(1):156-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8980772</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 1997 Jan;175(1):222-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8985226</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>EMBO J. 1997 May 15;16(10):2576-89</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9184205</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Gen Genet. 1997 Sep;256(2):104-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9349701</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Antimicrob Chemother. 1998 Dec;42(6):747-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10052898</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Immun. 2000 Feb;68(2):982-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10639477</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
</list>
<tree><noCountry><name sortKey="Blankenship, Jill R" sort="Blankenship, Jill R" uniqKey="Blankenship J" first="Jill R" last="Blankenship">Jill R. Blankenship</name>
<name sortKey="Heitman, Joseph" sort="Heitman, Joseph" uniqKey="Heitman J" first="Joseph" last="Heitman">Joseph Heitman</name>
<name sortKey="Onyewu, Chiatogu" sort="Onyewu, Chiatogu" uniqKey="Onyewu C" first="Chiatogu" last="Onyewu">Chiatogu Onyewu</name>
<name sortKey="Perfect, John R" sort="Perfect, John R" uniqKey="Perfect J" first="John R" last="Perfect">John R. Perfect</name>
<name sortKey="Schell, Wiley A" sort="Schell, Wiley A" uniqKey="Schell W" first="Wiley A" last="Schell">Wiley A. Schell</name>
</noCountry>
<country name="États-Unis"><noRegion><name sortKey="Steinbach, William J" sort="Steinbach, William J" uniqKey="Steinbach W" first="William J" last="Steinbach">William J. Steinbach</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001889 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001889 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    RapamycinFungusV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:15105118
   |texte=   In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:15105118" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a RapamycinFungusV1

This area was generated with Dilib version V0.6.38.
Data generation: Thu Nov 19 21:55:41 2020. Site generation: Thu Nov 19 22:00:39 2020

	Serveur d'exploration sur la rapamycine et les champignons
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la rapamycine et les champignons

In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus.

In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki